The Recombinant Cynomolgus B7-H6/NCR3LG1 Protein is a high-quality recombinant protein produced for advanced research applications in molecular biology and biotechnology. This protein serves as a critical reagent in various experimental contexts, including functional studies, binding assays, and therapeutic development programs, providing researchers with a standardized and reliable tool for investigating protein function and interactions.
This product (SKU: RPCB2092) is produced using HEK293 cells and features a C-His tag for convenient detection and purification. The protein exhibits a calculated molecular weight of 27.6 kDa with an observed molecular weight of 40-52 kDa under denaturing conditions, achieving ≥ 95 % as determined by Tris-Bis PAGE;≥ 95 % as determined by HPLC., ensuring exceptional quality and consistency for research applications.
High quality, high purity and low endotoxin recombinant Recombinant Cynomolgus B7-H6/NCR3LG1 Protein (RPCB2092), tested reactivity in HEK293 cells and has been validated in SDS-PAGE.100% guaranteed.
Endotoxin:
< 1 EU/μg of the protein by LAL method.
Purity:
≥ 95 % as determined by Tris-Bis PAGE;≥ 95 % as determined by HPLC.
Reconstitution:
Centrifuge the tube before opening. Reconstitute to a concentration of 0.1-0.5 mg/mL in sterile distilled water. Avoid vortex or vigorously pipetting the protein. For long term storage, it is recommended to add a carrier protein or stablizer (e.g. 0.1% BSA, 5% HSA, 10% FBS or 5% Trehalose), and aliquot the reconstituted protein solution to minimize free-thaw cycles.
Storage:
Store at -20℃.Store the lyophilized protein at -20℃ to -80 ℃ up to 1 year from the date of receipt. After reconstitution, the protein solution is stable at -20℃ for 3 months, at 2-8℃ for up to 1 week.
B7-H6 is a glycosylated member of the B7 family of immune co?stimulatory proteins. which is a ligand for the NK cell activating receptor NKp30, was targeted to create a CAR that targets multiple tumor types. B7H6 is expressed on various primary human tumors, including leukemia, lymphoma and gastrointestinal stromal tumors, but it is not constitutively expressed on normal tissues.
Recombinant Cynomolgus B7-H6/NCR3LG1 Protein was determined by Tris-Bis PAGE under reducing conditions.
The purity of Cynomolgus B7-H6 is greater than 95% as determined by SEC-HPLC.
